VRCA - Verrica Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.09
-0.03 (-0.27%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close11.12
Open11.12
Bid0.00 x 800
Ask0.00 x 900
Day's Range10.78 - 11.70
52 Week Range6.44 - 23.29
Volume37,388
Avg. Volume48,330
Market Cap284.973M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.33
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Verrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting

    WEST CHESTER, Pa., Feb. 12, 2019 -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical.

  • GlobeNewswire2 months ago

    Verrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy

    Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced the appointment of Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy. "We are delighted to welcome Neil to our team and look forward to leveraging his deep industry experience as the company prepares for the potential launch of VP-102 for molluscum contagiosum," commented Ted White, President and Chief Executive Officer of Verrica. Mr. DeHenes brings to Verrica extensive experience in end-to-end commercialization support across the design, evaluation, implementation, and execution of channel strategy, patient services, co-pay offerings, third party logistics, and government program operations.

  • West Chester pharma firm to seek FDA OK for skin treatment
    American City Business Journals2 months ago

    West Chester pharma firm to seek FDA OK for skin treatment

    The company posted positive results from two late-stage studies of its experimental treatment for a highly contagious skin disease that afflicts primarily children.

  • GlobeNewswire2 months ago

    Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum

    WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) --  Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced positive topline results from its Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102 for the treatment of molluscum contagiosum (molluscum). Both clinical trials evaluated the safety and efficacy of VP-102, a proprietary drug-device combination containing a novel topical solution of 0.7% cantharidin, compared to placebo. In each trial, VP-102 exhibited a clinically and statistically significant proportion of subjects demonstrating complete clearance of all treatable molluscum lesions versus placebo.

  • Are Insiders Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock?
    Simply Wall St.2 months ago

    Are Insiders Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • PhaseBio goes public in downsized $46M IPO
    American City Business Journals4 months ago

    PhaseBio goes public in downsized $46M IPO

    Malvern biopharmaceutical company PhaseBio has become the third local life sciences company to go public through an IPO in 2018.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...

  • Benzinga7 months ago

    Analysts Call Verrica A Buy For Vast Molluscum Opportunity

    Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) at its June 15 IPO are celebrating 13.1-percent returns. The gains should continue, in the view of two new sell-side bulls. The Ratings ...